Drugs / rhDNase I
rhDNase I
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07361224 | May 2026 → Feb 2027 expected | large B-cell lymphoma | Tel-Aviv Sourasky Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04409925 | Dec 2020 → Apr 2021 | COVID-19 | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT02702518 Comparator | Apr 2016 → Apr 2020 | dry eye syndrome, graft versus host disease | University of Illinois at Chicago | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhDNase I | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07361224 ↗ |
| Known as | deoxyribonuclease I | “Recombinant Deoxyribonuclease I Eye Drops for Ocular Graft Versus Host Disease: Results of a Randomized Clinical Trial.” PMID 38407974 ↗ Feb 2024 |
| Known as | DNAase | “clinical trial using deoxyribonuclease I (DNAase) eye drops to test the hypothesis that reducing the abundance of NETs from the ocular surface will reduce signs and symptoms of oGVHD.” PMID 38407974 ↗ Feb 2024 |
| Known as | rhDNase | “A Phase I/II Randomized Placebo-Controlled, Double-Blind, Single-Center, Tolerability and Preliminary Efficacy Clinical Trial of Recombinant Human Deoxyribonuclease (rhDNase)...” NCT02702518 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Deoxyribonuclease (rhDNase) Eye Drops” NCT02702518 ↗ |
| Route | Topical | “rhDNase I, 0.1% eye drops 4 times a day for 8 weeks” NCT02702518 ↗ |